|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Ra Pharmaceuticals Inc (RARX)
Trading: HOLD @ $46.86
Signal Strength: STRONG
Indicator is best used in conjunction with additional indicators as it has the ability to highlight potential overbought or oversold levels. This indicator utilizes upper and lower bands to visually represent price extremes associated with the bands. Additional value can be added to the trading strategy by accessing divergences between price and volume.
Ra Pharmaceuticals Inc (NASDAQ:RARX) is currently bullish highlighting the potential for a short term trend continuation in the upward direction.
The Donchian channel is a useful indicator for seeing the volatility of a market price. If a price is stable the Donchian channel will be relatively narrow. If the price fluctuates a lot the Donchian channel will be wider. The two outer bands are plotted as the highest high and lowest low for a set period originally 20 days with the optional middle band calculated as the average of the two.
Calculation: Donchian Channels:
1) Upper Channel = 20 Day High;
2) Lower Channel = 20 Day Low;
3) Middle Channel = (20 Day High + 20 Day Low)/2;
PROFILE: Ra Pharmaceuticals Inc (RARX)
Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
|INO Inovio Pharma||3.84||11.6||12,215,392||27.39||BULLISH|
|NVAX Novavax Inc||7.66||8||16,617,930||13.24||BULLISH|
|CTXS Citrix Systems Inc||128.48||7.8||3,900,635||39.9||BULLISH|
|INTC Intel Corp||67.49||7.6||40,092,378||50||BULLISH|
|ADRO Aduro Biotech||1.59||7.4||1,186,588||50||BULLISH|
|JBLU Jetblue Airways||21.07||6.4||15,757,756||47.38||BULLISH|
|PFBC Preferred Bank||63.98||6.4||274,903||41.95||BULLISH|
|MESO Mesoblast Ads||10.57||5.8||172,816||48.88||BULLISH|
|MBUU Malibu Boats||43.99||5.7||198,176||46.56||BULLISH|
|NVEE Nv5 Global||60.14||5.1||352,073||47.16||BULLISH|